Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study
Salim Yusuf(Population Health Research Institute), Gilles R. Dagenais(Institut universitaire de cardiologie et de pneumologie de Québec), Andreas Wielgosz(University of Ottawa), Karen Yeates(Queen's University), Romaina Iqbal(Aga Khan University), Rafael Díaz(Estudios Clínicos Latinoamérica), Khalid Yusoff(Universiti Teknologi MARA), Patricio López‐Jaramillo(Universidad De Santander), Martin McKee(London School of Hygiene & Tropical Medicine), Andrew Mente(McMaster University), Viswanathan Mohan(Madras Diabetes Research Foundation), Iolanthé M. Kruger(North-West University), Katarzyna Zatońska(Wroclaw Medical University), Scott A. Lear(Simon Fraser University), Roya Kelishadi(Isfahan University of Medical Sciences), Koon Teo(Population Health Research Institute), Khalid F. AlHabib(King Saud University), Annika Rosengren(Sahlgrenska University Hospital), Philip Joseph(Population Health Research Institute), Shofiqul Islam(Population Health Research Institute), Darryl P. Leong(Population Health Research Institute), Sumathy Rangarajan(McMaster University), Manmeet Kaur(Post Graduate Institute of Medical Education and Research), Afzalhussein Yusufali(Dubai Health Authority), Omar Rahman(Independent University), V. Raman Kutty(Health Action by People), Álvaro Avezum(Sociedade de Nefrologia do Estado de São Paulo), Martin O’Donnell(Ollscoil na Gaillimhe – University of Galway), Jephat Chifamba(University of Zimbabwe), Aytekin Oğuz(Istanbul Medeniyet University), Michael Bräuer(University of British Columbia), Prem Mony(St. John's National Academy of Health Sciences), Rasha Khatib(Birzeit University), Perry Hystad(Oregon State University), Wei Li(Nanchong Central Hospital), Rajeev Gupta(Eternal Hospital), Fernando Laņas(Universidad de La Frontera), Antonio Dans(University of the Philippines Manila), Bo Hu(Kunming University of Science and Technology)
Cited by 1,955
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
|Journal of the American College of Cardiology|2020|11.1k